Pfizer is requesting proposals for the Maintenance Therapy in HER2+ Metastatic Breast Cancer (MBC) program.
Donor Name: Pfizer
State: All States
County: All Counties
Type of Grant: Grant
Deadline: 10/01/2025
Size of the Grant: $100,000 to $500,000
Grant Duration: Grant Duration Not Mentioned
Details:
Funding Information
Individual projects requesting $10,000 – $250,000 will be considered. The estimated total available budget related to this RFP is $500,000.
Eligibility Criteria
Applicant organizations to this RFP must be based in the United States:
- The following may apply: medical, allied health, and/or pharmacy professional schools; hospitals and healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
- Only organizations are eligible to receive grants, not individuals or physician-owned medical practices or individual-physician-owned organizations.
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
- The applicant must be the project/program lead or an authorized designee of such individual (e.g., project/program lead’s grant coordinator).
- The project/program lead must be an employee or contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.
- For projects offering continuing education credit in the US, the requesting organization must be the accrediting organization.
For more information, visit Pfizer.
